Effect of Morning Versus Evening Perindopril on Blood Pressure Control in People With Type 2 Diabetes
Launched by YAOUNDE CENTRAL HOSPITAL · Jan 5, 2018
Trial Information
Current as of July 01, 2025
Completed
Keywords
ClinConnect Summary
Background: Renin-angiotensin system antagonists represent the mainstay of blood pressure (BP) lowering treatment options in people with diabetes. ACE inhibitors have a long half-life and offer the advantage of a single daily dose, usually empirically taken in the morning.
Objective: We assessed the influence of time of administration of ACE inhibitors on circadian BP control in type 2 diabetes (T2D) patients with stage 1 hypertension.
Methods: Twenty T2D patients (9 being women) with a mean age of 58.7 years, diagnosed with stage 1 of hypertension and naive to BP lowering medications, we...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Type 2 diabetes
- • Grade 1 hypertension
- • Informed consent
- Exclusion Criteria:
- • estimated creatinine clearance≤ 60ml/min
- • White coat hypertension after initial 24 hour ABPM
- • Previous antihypertensive treatment
- • Pregnant women
- • Individuals working during the night
- • Hyperkalemia
About Yaounde Central Hospital
Yaoundé Central Hospital is a leading medical institution in Cameroon, dedicated to advancing healthcare through innovative clinical research and patient care. As a prominent sponsor of clinical trials, the hospital is committed to enhancing medical knowledge and improving treatment options across various health conditions. With a multidisciplinary team of experienced healthcare professionals and researchers, Yaoundé Central Hospital fosters a collaborative environment that prioritizes patient safety and ethical standards. The institution plays a vital role in addressing local and global health challenges, contributing to the development of effective therapies and interventions that benefit diverse populations.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Trial Officials
Eugène Sobngwi, MD, PhD
Principal Investigator
Yaounde Central Hospital
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials